SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-23-124503
Filing Date
2023-04-28
Accepted
2023-04-28 08:27:00
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A d502404ddefa14a.htm DEFA14A 24588
2 GRAPHIC g502404dsp67.jpg GRAPHIC 29498
3 GRAPHIC g502404dsp67b.jpg GRAPHIC 43288
4 GRAPHIC g502404dspe.jpg GRAPHIC 920
5 GRAPHIC g502404dspf.jpg GRAPHIC 1793
  Complete submission text file 0001193125-23-124503.txt   130401
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36483 | Film No.: 23860491
SIC: 8071 Services-Medical Laboratories